November 11, 2025

Local Consolidative Therapy Enhances Outcomes With Osimertinib in EGFR-Mutant NSCLC

Osimertinib in combination with local consolidative therapy of radiation and/or surgery led to a significant extension of progression-free survival for patients with EGFR-mutant metastatic non–small c...

The ASCO Post

November 11, 2025

Final FLAURA2 Analysis Confirms First-Line Benefit of Osimertinib/Chemotherapy in EGFR-Positive NSCLC

The combination of osimertinib plus chemotherapy led to a median overall survival of 47.5 months compared with 37.6 months with osimertinib monotherapy in patients with EGFR-mutated advanced non–small...

The ASCO Post

November 10, 2025

Long-Term Safety and Management of Adverse Events Associated With Lorlatinib in ALK-Positive Metastatic NSCLC: A Fictional Case Study

Explore how lorlatinib transformed treatment outcomes for a patient with ALK-positive metastatic NSCLC while highlighting the importance of effective management strategies.

JADPRO

November 05, 2025

New Report: Lung Cancer Advancements Are Saving More Lives Than Ever, but Funding Cuts May Hinder Progress

The American Lung Association’s eighth annual “State of Lung Cancer” report highlights how the toll of lung cancer varies by state and examines key indicators throughout the United States, including n...

The ASCO Post

November 04, 2025

New Poll: Only 1 in 3 Link Alcohol to Cancer

“Individuals who drink alcohol were more likely to believe that alcohol consumption has no effect on cancer risk, which is alarming, given the growing burden of alcohol-related cancers in the United States."

Conexiant

October 17, 2025

Your Guide to Referring to the Center for Heart Rhythm Disorders

The Center for Heart Rhythm Disorders at Miami Cardiac & Vascular Institute offers streamlined, expert evaluation and management of arrhythmias.

Baptist Health South Florida

October 15, 2025

Dana-Farber Research News 10.15.2025

This twice-monthly newsletter highlights recently published research where Dana-Farber faculty are listed as first or senior authors. The information is pulled from PubMed and this issue notes papers published from September 16 - September 30.

Dana-Farber

October 14, 2025

FDA Approves Combination Regimen for Extensive-Stage SCLC

Lurbinectedin (Zepzelca) in combination with atezolizumab (Tecentriq) or atezolizumab and hyaluronidase-tqjs (Tecentriq Hybreza) was approved for maintenance treatment of adults with extensive-stage s...

The ASCO Post

October 14, 2025

Surgical Resection With EGFR TKI Demonstrates Promising PFS in EGFR-Mutant NSCLC

Resection of the primary thoracic tumor after EGFR tyrosine kinase inhibition demonstrated the ability to prolong disease control in patients with EGFR-mutant metastatic non–small cell lung cancer (NS...

The ASCO Post